Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

Loading...
Loading...
  • The Menarini Group and Radius Health Inc's RDUS data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.
  • The company says that elacestrant is the first oral selective estrogen receptor degrader (SERD) demonstrating a significant improvement in Progression-free survival (PFS) vs. standard of care (SOC) with manageable safety.
  • Elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and 45% in patients with an ESR1 mutation.
  • PFS was prolonged in all patients.
  • PFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population and 26.8% vs. 8.2% in the ESR1 mutation population
  • The most common treatment-emergent adverse events (AEs) in patients receiving elacestrant were mild or moderate gastrointestinal events.
  • Price Action: RDUS shares traded higher by 1.71% at $5.94 on the last check Friday.
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...